Aurora Cannabis Inc. (NASDAQ: ACB) is a leading Canadian company that focuses on the global medical cannabis market. This prominent cannabis stock operates in key regions like Canada, Europe, and Australia. The company aims to maintain strong financial discipline while strategically expanding its presence in nationally legal medical markets, reinforcing its position in the global cannabis industry.
On June 11, 2026, Aurora Cannabis announced its latest quarterly earnings report. The company reported an earnings per share (EPS) of -$0.01. This financial result was significantly better than the analyst consensus estimate, which had predicted a larger loss of -$0.07 per share, indicating a positive earnings beat for the cannabis producer.
In the same report, Aurora Cannabis announced quarterly revenue of $61.09 million. This figure impressively surpassed the estimated revenue of $54.42 million. This strong financial performance is primarily driven by robust growth in its global medical cannabis segment, which now accounts for a significant portion of its overall business and market share.
For the full fiscal year 2026, Aurora Cannabis reported a record annual global medical cannabis net revenue of $288.60 million, an impressive 18% increase from the prior year. As highlighted by PR Newswire, its Adjusted EBITDA, a key measure of profitability, also hit a record $53.80 million, showcasing the company's operational efficiency and financial health.
The company maintains a strong balance sheet with approximately $164.70 million in cash and no debt, a significant advantage in the competitive cannabis sector. Its current ratio of 3.06 demonstrates excellent liquidity, showing it has more than enough assets to cover short-term bills. However, Aurora Cannabis warns that fiscal 2027 will be a "reset year" due to upcoming policy changes, which could impact its future market outlook.
